Expression of the G1-S Modulators in Hepatitis B Virus-Related Hepatocellular Carcinoma and Dysplastic Nodule: Association of Cyclin D1 and p53 Proteins with the Progression of Hepatocellular Carcinoma

Deranged expression of cell cycle modulators has been reported to contribute to the development and progression of hepatocellular carcinoma (HCC). However, their expression patterns remain poorly understood in hepatitis B virus (HBV)-related HCC, which constitutes about 65-70% of HCC in Korea. The aims of this study were to evaluate the expressions of G1-S modulators in HBV-related HCCs and dysplastic nodules (DNs), and to correlate with the histopathologic features of HCCs. Immunohistochemical expressions of cyclin D1, cyclin E, p53, p27, p21, p16, Rb, and PCNA proteins were investigated in 80 HCCs and 22 DNs. Cyclin D1 overexpression showed positive relationships with advanced tumor stage, poor differentiation, larger tumor size, microvascular invasion, intrahepatic metastasis, no tumor capsule formation, infiltrative growth, aberrant p53 expression, and high PCNA labeling index (LI) of HCC (p<0.05). Aberrant p53 expression showed positive relationship with poor differentiation of HCC (p<0.01). Expression of cyclin D1 or p53 was not observed in DNs. The p27 LI and p16 LI were lower in HCCs with intrahepatic metastasis (p<0.05). Cyclin D1 overexpression and aberrant p53 expression could be associated with the progression of HBV-related HCC, and might have a less crucial role in the DN-HCC sequence. In addition, elevated expression of p27 and p16 proteins might have inhibitory action to the intrahepatic metastasis of HBV-related HCC.

Key Words: Carcinoma, Hepatocellular; Dysplastic Nodule; Hepatitis B Virus; Protein cyclin D1; Protein p53; Protein p27; Protein p16

INTRODUCTION

Uncontrolled cell proliferation is the hallmark of cancer, and tumor cells have acquired damage to genes that directly regulate their cell cycles. In the cell cycle, the period from the late G1 to the S phase is the most important for cell proliferation. The decision to divide occurs as cell passes a restriction point late in G1, after which they commit to the autonomous program that carries them through to division. The restriction point is regulated largely by retinoblastoma gene product (pRb). In pRb phosphorylation, two major G1 cyclins have important roles. Cyclin D1 forms a complex with cyclin-dependent kinase (cdk) 4 or cdk6, and works for the phosphorylation of pRb. Cyclin E binds to cdk2 and also phosphorylates pRb (1). Cyclin D1 gene is amplified in human carcinomas of esophagus (2) and breast (3). Deranged cyclin E mRNA expression has been reported in carcinomas of the breast (4). Rb gene is deleted or mutated in a wide range of human cancers (5).

To prevent unrestrained proliferation, there are a number of cyclin-dependent kinase inhibitors (CKIs) which bind with specific cdks, preventing the cdks from binding to cyclin and hence blocking a cascade of events which ultimately leads to cell proliferation. Two subtypes of CKIs are the INK (inhibitor of kinase) family, which includes p16 (INK4a), p15 (INK4b), p18 (INK4c) and p19 (INK4d), and the CIP/KIP (cdk interacting protein/kinase inhibitory protein) family, which includes p21 (WAF1/CIP1), p27 (KIP1) and p57 (KIP2) (6). After exposure to DNA damaging agent, wild-type p53 induced p21 protein expression allows apoptosis, thus, induction of p21 protein seems to occur with functional p53. In contrast, recent study has demonstrated that p21 can be induced by a p53-independent pathway (7). p16 is implicated in carcinogenesis as a result of frequent gene alterations such as deletion, mutation, and aberrant DNA methylation in human cancers (8). Unlike p16 gene, mutation of the p21 or p27 gene is an extremely rare event in human carcinomas (9-11).
p53 is considered to be a stress response gene, and its product (the p53 protein) induces cell cycle arrest or apoptosis in response to DNA damage. Mutation of p53 gene is the most common genetic abnormality identified in human carcinomas and may result in a biologically altered protein that is detectable by immunohistochemical method (12).

Proliferating cell nuclear antigen (PCNA) is an auxiliary protein for DNA polymerase-delta, and accumulates in the nucleus from the late G1 to the S phase. PCNA can be used as an immunohistochemical marker of proliferating cells (13).

Hepatocellular carcinoma (HCC) is one of the most common human malignancies, especially in sub-Saharan Africa and Southeast Asia including Korea (14). Hepatitis B and C viruses, alcohol and aflatoxin B1 are known risk factors for HCC. It is probable that the ongoing process of hepatocyte necrosis and liver cell renewal coupled with inflammation, which is characteristic of chronic viral hepatitis, causes not only cirrhosis but also progressive genomic errors in hepatocytes as well as unregulated growth and repair mechanism leading to hepatocyte dysplasia and, in some cases, HCC (15). Investigation of the cell proliferating status in HCC is important for evaluating the biological aggressiveness of HCC, because distant and lymphatic metastases are not very common. Recently, both genetic alterations and overexpressions of cell cycle modulators in HCC have been investigated, but there were small numbers of cases with hepatitis B virus (HBV)-related HCC (16-18). HBV-related HCC constitutes about 65-70% of HCC in Korea (19). It is probable that the ongoing process of hepatocyte necrosis and liver cell renewal coupled with inflammation, which is characteristic of chronic viral hepatitis, causes not only cirrhosis but also progressive genomic errors in hepatocytes as well as unregulated growth and repair mechanism leading to hepatocyte dysplasia and, in some cases, HCC (15). Investigation of the cell proliferating status in HCC is important for evaluating the biological aggressiveness of HCC, because distant and lymphatic metastases are not very common. Recently, both genetic alterations and overexpressions of cell cycle modulators in HCC have been investigated, but there were small numbers of cases with hepatitis B virus (HBV)-related HCC (16-18). HBV-related HCC constitutes about 65-70% of HCC in Korea (19). It is necessary to study on the cell cycle modulators for a large number of cases with HBV-related HCC for the prevention and treatment of HCC.

Dysplastic nodule (DN) has recently been described as a possible precancerous lesion in multistep hepatocarcinogenesis (20). Sequential development of low grade DN (LDN), high grade DN (HDN) and early HCC is very similar to multistep tumorigenesis in colon (21). In colorectal carcinogenesis, p53 mutation occurs in about 20% of adenomas and seems to be a rate-limiting step that makes an important contribution to tumor progression (22). p53 mutation might be an unusual event in DN (23). No crucial events or pivotal alterations in the molecular basis of the hepatocarcinogenesis have yet to be elucidated.

The aims of this study were to evaluate the expressions of cyclin D1, cyclin E, p53, p27, p21, p16, Rb, and PCNA proteins in HBV-related HCCs and DNs with a correlation with the histopathologic features of HCCs.

**MATERIALS AND METHODS**

**Tissue specimens and histopathology**

Eighty HCCs (Edmondson grade I, 20; grade II, 24; grade III, 36 cases) and 22 DNs (LDN, 10; HDN, 12 cases) were derived from 72 and 18 surgically resected livers, respectively, at Samsung Medical Center from 1996 to 1999. All patients were of Korean origin. The patients were diagnosed as HCC or liver cirrhosis, and undergone surgery without transcatheter arterial chemoembolization or lipiodol injection. All patients were seropositive for hepatitis B surface antigen (HBsAg), showed positive immunoreactivity for HBsAg in nontumor liver, and had no serum antibody against hepatitis C virus (HCV). Seventy two patients with HCC were 58 men and 14 women with a mean age at diagnosis of 55.2 yr (range, 31-79 yr). Seventeen patients with DN were 16 men and 2 women with a mean age at diagnosis of 56.1 yr (range, 33-79 yr). Tissue were fixed in 10% formalin for 12 hr and embedded in paraffin. Sections of 4-μm thickness were stained with hematoxylin and eosin. HCCs were graded histologically according to the Edmondson and Steiner (24), and DNs were classified according to the International Working Party (20) into two groups, i.e., LDN and HDN. Among the patients with HCC, 67 patients had single HCC, 2 patients had two HCCs, and 3 patients had three HCCs. Among the patients with DN, 15 patients had single DN, 2 patients had two DNs, and 1 patient had three DNs. Among the patients with HCC, 56 patients showed cirrhosis in nontumor liver, and 16 patients showed chronic hepatitis. All patients with DN showed cirrhosis in nontumor liver, and five patients with DN had no HCC. The histopathologic features of HCCs were examined: tumor stage, tumor size, histological differentiation, portal vein invasion, microvascular invasion, intrahepatic metastasis, tumor capsule formation, and growth pattern. The tumor stage was determined according to the TNM atlas (UICC) (25). Portal vein invasion was defined as tumor thrombus in the lobar or segmental branches of the portal veins. Microvascular invasion was considered as present when tumor was seen in a vessel, that is, at least 1 or more endothelial cells or the tunica media of the vessel were recognized to surround a neoplastic cell group. Intrahepatic metastasis and tumor capsule formation conformed to the Classification of Primary Liver Cancer of the Liver Cancer Study Group of Japan (26). The growth pattern was divided as infiltrative and expansive, and infiltrative pattern was defined as the presence of one or more foci of microscopic parenchymal invasion. Blocks of normal liver were prepared from 10 patients with metastatic colonic carcinoma of the liver as control cases.

**Immunohistochemistry**

Representative tissue sections including both HCC or DN and adjacent nontumorous liver were selected and sectioned in 4-μm thickness. Immunohistochemical study was performed using the streptavidin-biotin complex method and TechMate 1000 automated staining system (Dako Cytomation, Glostrup, Denmark). Primary antibodies used
and working dilutions employed were as follows: cyclin D1 (clone P2D11F11, monoclonal, 1:10), cyclin E (clone 13A3, monoclonal, 1:20), and Rb (clone IF8, monoclonal, 1:20) from Novocastra (London, UK), p21 (clone BP53.12, monoclonal, 1:25) and PCNA (clone PC10, monoclonal, 1:1000) from Dako (Glostrup, Denmark), p53 (clone BP53.12, monoclonal, 1:80), p27 (clone 57, monoclonal, 1:200), and p16 (rabbit polyclonal, 1:20) from Zymed (San Francisco, CA, U.S.A.), Transduction (Lexington, KY, U.S.A.), and Santa Cruz (Santa Cruz, CA, U.S.A.), respectively. Deperaffinized sections were treated with 3% hydrogen peroxide in methanol for 10 min to block endogenous peroxidase. Sections were processed in 0.05 M citrate buffer (pH 6.0) and heated in a microwave oven for 10 min for antigen retrieval. Sections were then incubated with the primary antibody for 60 min at room temperature. Each section was treated with biotinylated secondary antibody and streptavidin-peroxidase complex (Dako, Glostrup, Denmark), sequentially. DAB (3,3′-diaminobenzidine tetrahydrochloride) was used as a chromogen, and Mayer’s hematoxylin counterstain was applied. Negative controls were run simultaneously with an omission of primary antibody.

Immunohistochemical evaluation

For assessment of the positivity of immunostaining for each section, only nuclear staining was regarded as positive. We regarded the G1 cyclins and p53 as positive when ≥5% of tumor cell nuclei showed positive immunostaining.

We counted positive cells for p27, p21, p16, Rb and PCNA by monitoring at least 1,000 cells in HCC or DN and non-tumorous liver from more than five high power fields where positive cells were present at a relatively uniform density. Then, we calculated the labeling index (LI) as a percentage for each protein.

Table 1. Relationship between the overexpression of cyclin D1 protein and histopathologic features of hepatocellular carcinomas

| Categories          | Cyclin D1 positive cases | p value |
|---------------------|--------------------------|---------|
| Tumor stage I       | 2/27 (7.4%)              | 0.032   |
| Tumor stage II      | 3/21 (14.3%)             |         |
| Tumor stage III     | 7/20 (35.0%)             |         |
| Tumor stage IV      | 5/12 (41.7%)             |         |
| Tumor size ≤2 cm    | 2/32 (6.3%)              | 0.021   |
| Tumor size 2-5 cm   | 7/26 (26.9%)             |         |
| Tumor size >5 cm    | 8/22 (36.4%)             |         |
| Differentiation Ed I| 0/20 (0%)                | <0.001  |
| Differentiation Ed II| 2/24 (8.3%)            |         |
| Differentiation Ed III| 15/36 (41.7%)        |         |
| Portal vein invasion+| 3/10 (30.0%)            | NS      |
| Portal vein invasion−| 14/70 (20.0%)           |         |
| Microvascular invasion+| 12/37 (32.4%)         | 0.023   |
| Microvascular invasion−| 5/43 (11.6%)           |         |
| Intrahepatic metastasis+| 5/11 (45.5%)         | 0.049   |
| Intrahepatic metastasis−| 12/69 (17.4%)          |         |
| Capsule formation+   | 3/37 (8.1%)              | 0.003   |
| Capsule formation−   | 14/38 (36.8%)            |         |
| Growth pattern       |                          |         |
| Growth pattern Infiltrative | 10/27 (37.0%)    | 0.016   |
| Growth pattern Expansive | 7/53 (13.2%)       |         |
| p53 expression       |                          |         |
| p53 expression Positive | 9/18 (50.0%)          | 0.002   |
| p53 expression Negative  | 8/62 (12.9%)           |         |

Table 2. Relationship between the aberrant expression of p53 protein and histopathologic features of hepatocellular carcinomas

| Categories          | p53 positive cases | p value |
|---------------------|--------------------|---------|
| Tumor stage I       | 2/27 (7.4%)        | NS      |
| Tumor stage II      | 5/21 (23.8%)       |         |
| Tumor stage III     | 7/20 (35.0%)       |         |
| Tumor stage IV      | 4/12 (33.3%)       |         |
| Tumor size ≤2 cm    | 2/32 (6.3%)        | NS      |
| Tumor size 2-5 cm   | 9/26 (34.6%)       |         |
| Tumor size >5 cm    | 7/22 (31.8%)       |         |
| Differentiation Ed I| 0/20 (0%)          | 0.003   |
| Differentiation Ed II| 4/24 (16.7%)      |         |
| Differentiation Ed III| 14/36 (38.9%)     |         |
| Portal vein invasion+| 3/10 (30.0%)       | NS      |
| Portal vein invasion−| 15/70 (21.4%)     |         |
| Microvascular invasion+| 11/37 (29.7%)      | NS      |
| Microvascular invasion−| 7/43 (16.3%)      |         |
| Intrahepatic metastasis+| 3/11 (27.3%)      | NS      |
| Intrahepatic metastasis−| 15/69 (21.7%)     |         |
| Capsule formation+   | 8/37 (21.6%)       | NS      |
| Capsule formation−   | 10/38 (26.3%)      |         |
| Growth pattern       |                    |         |
| Growth pattern Infiltrative | 8/27 (29.6%)      | NS      |
| Growth pattern Expansive | 10/53 (18.9%)    |         |

Ed, Edmondson grade; NS, not significant
(p=0.016), and aberrant expression of p53 protein (p=0.002) (Table 1). The average LI of PCNA was significantly higher in cases with overexpression of cyclin D1 protein (cyclin D1 positive: 76.0±16.0, cyclin D1 negative: 56.3±27.0, p=0.018).

Only one case (1.3%) of stage III HCC showed overexpression of cyclin E protein (Fig. 1B).

Aberrant expression of p53 protein was observed in 18 of the 80 cases (22.5%) of HCC (Fig. 1C). There was positive correlation between the aberrant expression of p53 protein and poorer histological grade of differentiation (p=0.003) (Table 2). The average LI of PCNA was higher in cases with aberrant p53 protein expression, but there was no statistical significance (p=0.076).

Expression of cyclin D1, cyclin E, and p53 proteins was not observed in DN, nontumorous livers, and normal controls.

p27 protein was expressed in 64 cases (80%) of HCC.

Fig. 1. Representative examples of immunohistochemical staining of the G1-S modulators in HCCs (A-D, F, G, I) and dysplastic nodules (E, H, J). Overexpression of cyclin D1 (A) and cyclin E (B), and aberrant expression of p53 (C) in HCC Ed III. Nuclear immunoreactivity for p27 in HCC Ed II (D) and high grade dysplastic nodule (E). Nuclear immunoreactivity for p21 in HCC Ed III (F). (Fig. 1 continued next)
Fig. 1D) and its average LI was 45.3 ± 38.4. The p27 LI in HCC was significantly lower in cases with intrahepatic metastasis ($p=0.040$) (Table 3). p27 protein was expressed in 6 of the 12 cases (50%) of HDN (Fig. 1E) and 6 of the 10 cases (60%) of LDN. The average LIs of HDN, LDN, and nontumorous liver were 7.0 ± 11.9, 3.0 ± 4.1, and 8.0 ± 18.2, respectively (Table 5), and were significantly lower than that of HCC ($p<0.001$).

p21 protein was expressed in 18 cases (22.5%) of HCC (Fig. 1F) and its average LI was 0.6 ± 1.8. No correlation could be established between the p21 LI and histopathologic features of HCCs, including aberrant expression of p53 protein (Table 3). p21 protein was not expressed in DNs and nontumorous livers (Table 5).

p16 protein was expressed in 58 cases (72.5%) of HCC (Fig. 1G) and its average LI was 35.2 ± 37.4. p21 LI in HCC was significantly lower in cases with intrahepatic metastasis ($p=0.012$) (Table 3), and there was no association with the pRb LI. p16 protein was expressed in 6 cases (50%) of HDN (Fig. 1H) and 6 cases (60%) of LDN. The average LIs of HDN, LDN, and nontumorous liver were 9.5 ± 16.1, 1.8 ± 2.1, and 9.0 ± 23.8, respectively (Table 5), and were significantly lower than that of HCC ($p<0.001$).

Rb protein was expressed in 62 cases (77.5%) of HCC (Fig. 1I) and its average LI was 34.6 ± 35.6. There was no statistically significant correlation between the pRb LI and histopathologic features of HCCs (Table 4). Rb protein was expressed in 7 cases (58.3%) of HDN (Fig. 1J) and 5 cases (50%) of LDN. The average LIs of HDN, LDN, and nontumorous liver were 17.5 ± 21.4, 1.3 ± 2.0, and 5.9 ± 13.1, respectively (Table 5), and were significantly lower than that of HCC ($p<0.05$).

The average PCNA LIs of nontumorous liver, LDN, HDN, and HCC were 2.3 ± 1.2, 3.8 ± 2.6, 10.0 ± 9.7, and 33.3 ± 21.7 (Edmondson I, 10.1 ± 7.1; Edmondson II, 23.6 ± 12.4; Edmondson III, 43.3 ± 21.2), respectively (Table 5). The PCNA LI significantly increased from LDN to HDN, and from HDN to HCC ($p<0.001$). The PCNA LI in HCC was significantly higher in more poorly differentiated lesions ($p=0.000$).

There were no significant differences between the average LI of p27, p21, p16, and Rb proteins in nontumorous liver and those in normal controls.

Fig. 1. (Continued from the previous page) Nuclear immunoreactivity for p16 in HCC Ed II (G) and high grade dysplastic nodule (H). Nuclear immunoreactivity for Rb in HCC Ed II (I) and high grade dysplastic nodule (J). ($\times$ 200). Ed: Edmondson grade.
G1-S Modulators in HBV-Related Hepatocellular Carcinoma 429

LI, labeling index; Ed, Edmondson grade; NS, not significant

Table 3. Relationship between the expression of p27, p21 and p16 proteins, and histopathologic features of hepatocellular carcinomas

| Categories          | p27 LI | p value | p21 LI | p value | p16 LI | p value |
|---------------------|--------|---------|--------|---------|--------|---------|
| Tumor stage         |        |         |        |         |        |         |
| I                   | 29.4 ± 21.2 | NS | 0.2 ± 0.8 | NS | 31.3 ± 28.9 | NS |
| II                  | 61.3 ± 63.0 | 0.1 ± 0.3 | 42.8 ± 39.5 | |
| III                 | 50.2 ± 44.3 | 0.5 ± 0.8 | 40.0 ± 42.2 | |
| IV                  | 38.3 ± 33.2 | 2.1 ± 1.9 | 23.0 ± 28.1 | |
| Tumor size          |        |         |        |         |        |         |
| <2 cm               | 37.3 ± 39.1 | NS | 0.2 ± 0.3 | NS | 37.1 ± 34.3 | NS |
| 2-5 cm              | 45.6 ± 44.9 | 0.5 ± 0.8 | 30.7 ± 33.2 | |
| >5 cm               | 54.3 ± 52.2 | 1.1 ± 2.1 | 38.3 ± 35.5 | |
| Differentiation     |        |         |        |         |        |         |
| Ed I                | 38.5 ± 41.5 | NS | 0.1 ± 0.7 | NS | 35.5 ± 37.2 | NS |
| Ed II               | 53.1 ± 55.1 | 0.3 ± 0.4 | 37.9 ± 40.9 | |
| Ed III              | 43.8 ± 33.3 | 1.0 ± 0.7 | 33.2 ± 31.6 | |
| Portal vein         |        |         |        |         |        |         |
| +                   | 38.0 ± 40.4 | NS | 2.1 ± 3.1 | NS | 6.0 ± 11.1 | NS |
| invasion            | 46.6 ± 37.8 | 0.3 ± 0.9 | 36.9 ± 32.3 | |
| Microvascular       |        |         |        |         |        |         |
| +                   | 49.2 ± 47.2 | NS | 0.2 ± 0.5 | NS | 37.0 ± 39.0 | NS |
| invasion            | 42.1 ± 39.2 | 1.0 ± 0.4 | 33.8 ± 31.7 | |
| Intrahepatic        |        |         |        |         |        |         |
| +                   | 15.8 ± 19.5 | 0.040 | 0.6 ± 0.7 | NS | 9.2 ± 12.1 | 0.012 |
| metastasis          | 50.5 ± 47.2 | 0.6 ± 0.6 | 39.8 ± 34.1 | |
| Capsule             |        |         |        |         |        |         |
| +                   | 47.6 ± 42.9 | NS | 0.9 ± 1.1 | NS | 39.2 ± 30.2 | NS |
| formation           | 46.3 ± 44.2 | 0.2 ± 0.3 | 34.2 ± 33.6 | |
| Growth pattern      |        |         |        |         |        |         |
| Infiltrative        | 42.0 ± 40.8 | NS | 0.3 ± 0.4 | NS | 29.0 ± 34.3 | NS |
| Expansive           | 47.0 ± 39.6 | 1.2 ± 2.1 | 38.6 ± 39.1 | |

Table 4. Relationship between the expression of Rb protein and histopathologic features of hepatocellular carcinomas

| Categories         | Rb LI | p value |
|--------------------|-------|---------|
| Tumor stage        |       |         |
| I                  | 24.0 ± 26.7 | NS |
| II                 | 43.9 ± 44.2 | |
| III                | 34.2 ± 38.2 | |
| IV                 | 39.7 ± 35.9 | |
| Tumor size         |       |         |
| <2 cm              | 27.8 ± 29.1 | NS |
| 2-5 cm             | 39.2 ± 33.3 | |
| >5 cm              | 40.3 ± 48.2 | |
| Differentiation    |       |         |
| Ed I               | 26.2 ± 29.7 | NS |
| Ed II              | 39.7 ± 38.3 | |
| Ed III             | 35.8 ± 32.2 | |
| Portal vein        |       |         |
| +                  | 46.0 ± 48.5 | NS |
| invasion           | 33.1 ± 33.5 | |
| Microvascular      |       |         |
| +                  | 37.9 ± 39.1 | |
| invasion           | 32.2 ± 29.4 | |
| Intrahepatic       |       |         |
| +                  | 15.8 ± 11.1 | NS |
| metastasis         | 37.2 ± 42.0 | |
| Capsule            |       |         |
| +                  | 36.7 ± 38.8 | NS |
| formation          | 33.6 ± 35.9 | |
| Growth pattern     |       |         |
| Infiltrative       | 33.3 ± 29.9 | NS |
| Expansive          | 35.3 ± 40.1 | |

Table 5. Average labeling indices of p27, p21, p16, Rb, and PCNA proteins in hepatocellular carcinomas and dysplastic nodules

| Categories | p27 LI | p21 LI | p16 LI | Rb LI | PCNA LI |
|------------|--------|--------|--------|-------|---------|
| HCC        |        |        |        |       |         |
| HDN        | 7.0    | 9.5    | 17.5   | 10.0  | 33.3    |
| LDN        | 3.0    | 1.8    | 3.8    |       |         |

HCC, hepatocellular carcinoma; HDN, high grade dysplastic nodule; LDN, low grade dysplastic nodule; LI, labeling index

DISCUSSION

Hepatitis B virus is an important etiologic factor that contributes to HCC, but there have been few studies for a large number of cases with HBV-related HCC. Nishida et al. (27) demonstrated that amplification and overexpression of cyclin D1 gene in both HBV- and HCV-related HCCs at an advanced stage with rapid tumor growth. However, a recent study reported that downregulation of cyclin D1 mRNA was significantly associated with large HCC and did not correlate with serum HBSAg (18). Ito et al. (16) reported that cyclin D1 protein overexpression occurred more frequently in HCCs with poor differentiation (p=0.0612) and intrahepatic metastasis (p=0.0675), and did not correlate with serum HBSAg or HCV antibody. In this study, overexpression of cyclin D1 protein showed positive relationship with advanced tumor stage, poor differentiation, larger tumor size, microvascular invasion, intrahepatic metastasis, no tumor capsule formation, and infiltrative growth of HBV-related HCCs. But cyclin D1 protein overexpression was not observed in DNs. Our findings strongly suggest that cyclin D1 protein overexpression occurs after the initial stage of hepatocellular carcinogenesis, and reflects the progression and aggressiveness of HBV-related HCCs. Cyclin D1 alterations might be an unusual event in DNs, and might have a less crucial role in the DN→HCC sequence.
We also found that overexpression of cyclin D1 protein was significantly associated with aberrant expression of p53 protein, which suggests that overexpression of cyclin D1 and p53 proteins can lead to deregulation of cell cycle and contribute to the progression of HBV-related HCC. The PCNA LI was higher in HCCs with overexpression of cyclin D1 protein, which suggests that cyclin D1 protein is related to the dedifferentiation and proliferative activity of HBV-related HCCs.

In this study, the histological differentiation of HCCs correlated with the aberrant p53 protein expression, and there was no p53 protein expression in DNs. We suggest that p53 alterations may be an unusual event in the precancerous lesions of multistep hepatocarcinogenesis, and might have a less crucial role in the DN-HCC sequence. p53 alterations seem to be a relatively late occurring event and related to the aggressiveness of HCC (16). And it is suggested that p53 alterations play a less important role in the progression of HBV-related HCCs than cyclin D1 alterations.

Peng et al. (18) reported that overexpression of cyclin E mRNA was observed in 56.3% of HCC, was significantly associated with poorly differentiated and invasive HCCs, and did not correlate with serum HBsAg. Ito et al. (16) reported that cyclin E protein overexpression was observed in 35.5% of HCC, and had positive relationship with stage of HCC. In the present study, cyclin E protein overexpression was observed in 1.3% of HCC. Since the histopathologic features do not differ in HCCs from various geographic areas, the discrepancy in frequency of cyclin E alterations may indicate that these changes do not represent a primary oncogenic event but are a late event in tumor progression. Alternatively, the existence of a different genetic background for the etiology of HCCs in different human populations could be postulated.

p27 protein is expressed in high rate in normal tissue, but shows decrease or absence of expression in tumor tissue, indicating an unfavorable factor in human cancers (28-30). In this study, the average LI of p27 protein was higher in HCC than in nontumorous liver or DN, unlike other cancers. Our finding is consistent with the recent report (16). We found that the p27 LI was significantly lower in HCCs with intrahepatic metastasis (p=0.040). This study offers the evidence for a potential role of p27 dysfunction in the process of HCC metastasis. Ito et al. (16) reported that the decreased expression of p27 protein in HCC was strikingly related to the biological aggressiveness, including portal vein invasion, poor differentiation, and larger size of HCCs as well as its prognosis, and that the p27 LI decreased with borderline significance in cases with intrahepatic metastasis (p=0.078). A previous study demonstrated that the lack or decreased expression of this protein is regulated at posttranslational levels of p27 gene by a ubiquitin-proteasome pathway (31), instead of common gene mutations or aberrant DNA methylation. The decreased p27 protein expression in advanced HCC may be derived by the same mechanism.

Recent studies demonstrated that p21 is an important cell cycle regulatory factor in continuously proliferating cells. Little p21 protein or mRNA is detected in normal human liver tissue, but hepatocyte p21 expression is upregulated in response to hepatic injury (32, 33). The absence of p21 protein expression in nontumorous liver in this study indicates that the level of p21 protein in hepatocytes is below the immunohistochemically detectable threshold, which might be due to the low proliferative activity in nontumorous liver. Down-regulation of p21 expression through degradation by a ubiquitin-dependent proteolytic pathway has recently been reported (34). Our results showed that the average LI of p21 protein was very low in HCC, which suggests that post-transcriptional regulation might be one mechanism that down-regulate p21 expression in HCC. In this study, there was no correlation between the p21 protein expression and histopathologic features of HCCs, which is consistent with the recent reports (35, 36).

A recent study demonstrated that epigenetic change due to extensive CpG methylation is the main cause of inactivation of p16(INK4a) in HCC (37). In this study, the average LI of p16 protein was higher in HCC than in nontumorous liver, which is consistent with the recent report (16). We demonstrated that the p16 LI was significantly lower in HCCs with intrahepatic metastasis (p=0.012). This study offers the evidence for a potential role of p16 dysfunction in the process of HCC metastasis. Hui et al. (38) suggested that p16 protein loss might contribute to the progression of HCC, because it occurred approximately twice as often in advanced rather than in early stage HCC.

The loss of pRb expression in HCC is mainly caused by loss of heterozygosity of the Rb gene (39). In this study, the average LI of pRb was higher in HCC than in nontumorous liver, which is consistent with the recent report (16). Hui et al. (40) suggested that elevated and absent pRb is closely associated with tumor progression and developing metastatic disease rather than tumor initiation in HCC. We could not determine any correlation between the pRb expression and histopathologic features of HCCs, which is consistent with previous reports (16, 41).

The PCNA LI, in this study, was significantly higher in more poorly differentiated HCCs, which is consistent with previous reports (42, 43). Our finding suggests that cell proliferative activity of HCC cells correlates with their degree of dedifferentiation. We also found that the PCNA LI increased from LDN, to HDN, and to HCC, which is consistent with previous report (43).

In summary, the present study suggests that overexpression of cyclin D1 protein and aberrant expression of p53 protein could be associated with the progression of HBV-related HCC, but might not be related to the DN-HCC sequence. In addition, elevated expression of p27 and p16 proteins might have inhibitory action to the intrahepatic
metastasis of HBV-related HCC.

REFERENCES

1. Schafer KA. The cell cycle: a review. Vet Pathol 1998; 35: 461-78.
2. Jiang W, Kahn SM, Tomita N, Zhang YJ, Lu SH, Weinstein IB. Amplification and expression of human cyclin D gene in esophageal cancer. Cancer Res 1992; 52: 2980-3.
3. Keyomarsi K, Pardee AB. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci USA 1993; 90: 1112-6.
4. Keyomarsi K, O’Leary N, Molnar G, Lees E, Fingert HJ, Pardee AB. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 1994; 54: 380-5.
5. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-30.
6. Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672-7.
7. Michiell P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 1994; 54: 3391-5.
8. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D. CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995; 1: 686-92.
9. Shiohara M, el-Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R, Chen DL, Vogelstein B, Koeffler HP. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994; 84: 3781-4.
10. Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, Takeuchi S, Hatta Y, Simpison J, Wilczynski S, Lee YY, Bartram CY, Koeffler HP. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27Kip1 in human malignancies. Cancer Res 1995; 55: 2266-9.
11. Chen TC, Ng KF, Lien JM, Jeng LB, Chen MF, Hsieh LL. Mutational analysis of the p53 codon 27 gene in hepatocellular carcinoma. Cancer Lett 2000; 153: 169-73.
12. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-78.
13. Hall PA, Levison DA, Woods AL, Yu CC, Kellock DH, Watts AS, Barnette PA, Dzau VJ, Waters WH, Lane DP. Proliferating cell nuclear antigen immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated DP. Cancer Res 1990; 50: 7717-22.
14. Di Bisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, Lotze MT. Hepatocellular carcinoma. Ann Intern Med 1988; 108: 191-209.
15. Idilman R, De Maria N, Colantoni A, Van Thiel DH. Pathogenesis of hepatitis B and Cinduced hepatocellular carcinoma. J Viral Hepatitis 1998; 5: 285-99.
16. Ito Y, Matsuura N, Sakon M, Miyoshi E, Noda K, Takeda T, Umeshita K, Nagano H, Nakamori S, Dono K, Tsujiimoto M, Nakahara M, Nakao K, Tanikuchi N, Mondon M. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. Hepatology 1999; 30: 90-9.
17. Naka T, Toyota N, Kaneko T, Kaibara N. Protein expression of p53, p21WAF1, and Rb as prognostic indicators in patients with surgically treated hepatocellular carcinoma. Anticancer Res 1998; 18: 555-64.
18. Peng SY, Chou SP, Hsu HC. Association of downregulation of cyclin D1 and of overexpression of cyclin E with p53 mutation, high tumor grade and poor prognosis in hepatocellular carcinoma. J Hepatol 1998; 29: 281-9.
19. Moon HY, Moon YM, Han KH, Chun YJ, Kang JK, Park IS. Clinical aspect and prognosis according to the infection type of hepatitis virus in primary liver cancer. Korean J Med 1994; 47(Suppl): 33.
20. International working party. Terminology of nodular hepatocellular lesions. Hepatology 1995; 22: 983-93.
21. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67.
22. Baker SJ, Preisinger AC, Jessup MJ, Paraskeva C, Markowitz S, Willson JK, Hamilton S, Vogelstein B. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990; 50: 7717-22.
23. Ang YK, Kim CJ, Kim EH, Kim HO, Kang GH, Kim YL. p53 mutation and overexpression in hepatocellular carcinoma and dysplastic nodules in the liver. Virchows Arch 1998; 432: 27-32.
24. Edmondson HA, Steiner PE. Primary carcinoma of the liver. A study of 100 cases among 4890 necropsies. Cancer 1954; 7: 462-502.
25. Hermanek P, Hutter RVP, Sobin LH, Wagner G, Wittekind CH. TNM atlas. 4th ed. UICC. Berlin: Springer, 1999; 115-23.
26. Liver Cancer Study Group of Japan. Classification of primary liver cancer. 1st ed. Tokyo: Kanehara press, 1997; 9-38.
27. Nishida N, Fukuda Y, Komeda T, Kita R, Sandu T, Furukawa M, Amenomori M, Shibagaki I, Nakao K, Ikemaga M, Ishizaki K. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res 1994; 54: 3107-10.
28. Wu J, Shen ZZ, Lu JS, Jiang M, Han QX, Fontana JA, Barsky SH, Shao ZM. Prognostic role of p27Kip1 expression and apoptosis in human breast cancer. Br J Cancer 1999; 79: 1572-8.
29. Lu CD, Morita S, Ishibashi T, Hara H, Itozaki H, Tanigawa N. Loss of p27kip1 expression independently predicts poor prognosis for patients with resectable pancreatic adenocarcinoma. Cancer 1999; 85: 1250-60.
30. Tenjo T, Toyoda M, Okuda J, Watanabe I, Yamamoto T, Tanaka K, Ohtani M, Nohara T, Kawasaki H, Tanigawa N. Prognostic significance of p27(KIP1) protein expression and spontaneous apoptosis in patients with colorectal adenocarcinomas. Oncology 2000; 58: 45-51.
31. Pagano M, Tan SW, Theodorsen AM, Beer-Romero P, DelSal G, Chau Y, Yew PR, Draett GA, Rolfe M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269: 682-5.
32. Crary GS, Albrecht JH. Expression of cyclin-dependent kinase inhibitor p21 in human liver. Hepatology 1998; 28: 738-43.
33. Albrecht JH, Meyer AH, Hu MY. Regulation of cyclin-dependent
kinase inhibitor p21\textsuperscript{WAF1/CIP1} gene expression in hepatic regeneration. Hepatology 1997; 25: 557-63.

34. Maki CG, Howley PM. Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol Cell Biol 1997; 17: 355-63.

35. Shi YZ, Hui AM, Takayama T, Li X, Cui X, Makuuchi M. Reduced p21 (WAF1/CIP1) protein expression is predominantly related to altered p53 in hepatocellular carcinomas. Br J Cancer 2000; 83: 50-5.

36. Kwon KW, Park YN, Park CI. p21 protein expression and cell proliferation activity in human multistep hepatocarcinogenesis. Korean J Pathol 2000; 34: 325-30.

37. Matsuda Y, Ichida T, Matsuzawa J, Sugimura K, Asakura H. p16\textsuperscript{(INK4)} is inactivated by extensive CpG methylation in human hepatocellular carcinoma. Gastroenterology 1999; 116: 394-400.

38. Hui AM, Sakamoto M, Kanai Y, Ino Y, Gotoh M, Yokota J, Hirohashi S. Inactivation of p16\textsuperscript{(INK4)} in hepatocellular carcinoma. Hepatology 1996; 24: 575-9.

39. Zhang X, Xu H-J, Murakami Y, Sachse R, Yashima K, Hirohashi S, Hu S-X, Benedict WF, Sekiya T. Deletions of chromosome 13q, mutation in retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res 1994; 54: 4177-82.

40. Hui AM, Li X, Makuuchi M, Takayama T, Kubota K. Over-expression and lack of retinoblastoma protein are associated with tumor progression and metastasis in hepatocellular carcinoma. Int J Cancer 1999; 84: 604-8.

41. Seki S, Kawakita N, Yanai A, Kitada T, Sakai Y, Nakatani K, Yamada T, Sakaguchi H, Kuroki T. Expression of the retinoblastoma gene product in human hepatocellular carcinoma. Hum Pathol 1995; 26: 366-74.

42. Mise K, Tashiro S, Yogita S, Wada D, Harada M, Fukuda Y, Miyake H, Isikawa M, Izumi K, Sano N. Assessment of the biological malignancy of hepatocellular carcinoma: Relationship to clinicopathological factors and prognosis. Clin Cancer Res 1998; 4: 1475-82.

43. Terada T, Nakanuma Y. Cell proliferative activity in adenomatous hyperplasia of the liver and small hepatocellular carcinoma. Cancer 1992; 70: 591-8.